Acura To Launch Nexafed PSE Despite Limits Of Extraction Resistance
This article was originally published in The Tan Sheet
Executive Summary
The spread of “one-pot” meth manufacturing will not deter Acura Pharmaceuticals from launching its OTC extraction-resistant PSE product, Nexafed. Making PSE products available in an extraction-resistant delivery formulation could offer an alternative to moving all dosages of the ingredient to the Rx class.
You may also be interested in...
Nexafed Gains Rite Aid Sales, But Stumbles In Extraction-Proof PSE Tests
As Nexafed distribution picks up momentum, Acura hits a setback in developing a 100% extraction-resistant formulation of its PSE decongestant. Rite Aid, the first national drug store chain to carry Nexafed, is selling only tamper-deterrent, single-ingredient PSE formulations in West Virginia and will consider making the change in other states.
Nexafed Gains Rite Aid Sales, But Stumbles In Extraction-Proof PSE Tests
As Nexafed distribution picks up momentum, Acura hits a setback in developing a 100% extraction-resistant formulation of its PSE decongestant. Rite Aid, the first national drug store chain to carry Nexafed, is selling only tamper-deterrent, single-ingredient PSE formulations in West Virginia and will consider making the change in other states.
Tamper-Resistant Pseudoephedrine Sparks Pharmacies’ Interest
Ohio and West Virginia chain Fruth Pharmacy begins replacing the 30 mg PSE products available in its stores with Acura Pharmaceuticals’ Nexafed product. Meanwhile, DEA says Westport Pharmaceuticals should not make an extraction-proof claim for its Zephrex-D PSE product.